Go online to PeerView.com/YGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The expanding therapeutic landscape for prostate cancer has provided new opportunities for oncology and urology professionals to improve outcomes through individualized patient care. With new and emerging strategies in both the hormone-sensitive and -resistant settings, treatment of patients with prostate cancer requires knowledge of next-generation anti-androgen agents, PARP inhibitors, and use of immunotherapy, radioligands, and other strategies alone or in active combinations, along with guidelines for testing and treatment. In this activity, urologic oncology experts pair in-depth analysis of efficacy and safety evidence with a case-focused discussion of best practices for bringing treatment advances to the clinic. Featured topics include novel therapeutic approaches, strategies for collaboration with other clinicians and patients to optimize care, and the role of clinical trials. Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended germline and somatic testing into the routine management of patients with prostate cancer to inform therapeutic decision-making; Describe the therapeutic roles, key efficacy and safety evidence, and current guideline recommendations pertaining to the use of novel and emerging prostate cancer treatment strategies; and Develop individualized treatment algorithms that incorporate new data and treatment options (including clinical trial enrollment), expert recommendations, shared decision-making, and multidisciplinary team-based care for patients with prostate cancer